Study to Assess the Efficacy Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

    Not Recruiting
  • participants needed
  • sponsor
    Aerpio Therapeutics
Updated on 13 June 2021
ophthalmic solution
brimonidine tartrate ophthalmic solution
ocular hypotensive
pigmentary glaucoma
latanoprost ophthalmic solution


This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM & PM) daily when used as an adjunctive therapy to latanoprost ophthalmic solution 0.005% once daily (PM) in subjects with elevated IOP due to OAG or OHT.

Condition EYE DISORDER, Ocular Hypertension, Glaucoma, Pigmentary glaucoma, Eye Disorders/Infections, Dry Eye Disease, Primary Open Angle Glaucoma, Eye Disorders/Infections (Pediatric), Eye Disease, Open Angle Glaucoma
Treatment Placebo, Latanoprost ophthalmic solution, AKB-9778
Clinical Study IdentifierNCT04405245
SponsorAerpio Therapeutics
Last Modified on13 June 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note